BR112022024533A2 - Formulação compreendendo daprodustat - Google Patents

Formulação compreendendo daprodustat

Info

Publication number
BR112022024533A2
BR112022024533A2 BR112022024533A BR112022024533A BR112022024533A2 BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2 BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A BR112022024533 A BR 112022024533A BR 112022024533 A2 BR112022024533 A2 BR 112022024533A2
Authority
BR
Brazil
Prior art keywords
daprodustat
formulation including
immediate release
release tablet
aspects
Prior art date
Application number
BR112022024533A
Other languages
English (en)
Inventor
Chattoraj Sayantan
Ryan Croy Scott
Anderson Mcleod James
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112022024533A2 publication Critical patent/BR112022024533A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÃO COMPREENDENDO DAPRODUSTAT. A presente divulgação refere-se a um comprimido de liberação imediata de daprodustat com resistência à tração satisfatória. Em outros aspectos, usos médicos do comprimido de liberação imediata e regimes de dosagem para usar o comprimido de liberação imediata são divulgados.
BR112022024533A 2020-06-19 2021-06-17 Formulação compreendendo daprodustat BR112022024533A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063041403P 2020-06-19 2020-06-19
US202063043292P 2020-06-24 2020-06-24
PCT/EP2021/066386 WO2021255159A1 (en) 2020-06-19 2021-06-17 Formulation comprising daprodustat

Publications (1)

Publication Number Publication Date
BR112022024533A2 true BR112022024533A2 (pt) 2022-12-27

Family

ID=76730508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024533A BR112022024533A2 (pt) 2020-06-19 2021-06-17 Formulação compreendendo daprodustat

Country Status (7)

Country Link
US (1) US20230225977A1 (pt)
EP (1) EP4167967A1 (pt)
JP (1) JP2023532223A (pt)
CN (1) CN115697307A (pt)
BR (1) BR112022024533A2 (pt)
CA (1) CA3180509A1 (pt)
WO (1) WO2021255159A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355734A1 (en) * 2021-06-18 2024-04-24 GlaxoSmithKline Intellectual Property (No. 2) Limited Novel manufacturing method of daprodustat and precursors thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
TWI795344B (zh) * 2015-06-30 2023-03-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
AU2018330994A1 (en) * 2017-09-15 2020-04-16 GlaxoSmithKline Intellectual Property (No. 2) Limited, England Crystalline forms of gsk1278863, preparation method and pharmaceutical use thereof
SG11202002113TA (en) * 2017-09-26 2020-04-29 Tesaro Inc Niraparib formulations
US20210387952A1 (en) * 2018-11-15 2021-12-16 Teva Pharmaceuticals International Gmbh Solid state forms of daprodustat and process for preparation thereof

Also Published As

Publication number Publication date
US20230225977A1 (en) 2023-07-20
CA3180509A1 (en) 2021-12-23
CN115697307A (zh) 2023-02-03
JP2023532223A (ja) 2023-07-27
EP4167967A1 (en) 2023-04-26
WO2021255159A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
BR112016028672A2 (pt) análogos de ribosídeo de nicotinamida e composições farmacêuticas e usos do mesmo
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
ECSP12012024A (es) Terapia combinada para el tratamiento del cáncer y ensayos de diagnóstico relacionados
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
AR063760A1 (es) Anticuerpos anti-factor d humanizados y usos de los mismos
BR112014030404A2 (pt) proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
AR061343A1 (es) Productos farmaceuticos uso de un antagonista de ccr5
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
ECSP12011735A (es) Composiciones que comprenden tramadol y celecoxib en el tratamiento del dolor
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112012008345A2 (pt) regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3
BR112022024533A2 (pt) Formulação compreendendo daprodustat
BRPI0513938B8 (pt) composição farmacêutica contendo drospirenona e etinilestradiol
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo